Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
once weekly for the first 8 weeks
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
oncology
hematology immunotherapy monoclonal antibody therapy |
| gptkbp:availableIn |
gptkb:Australia
gptkb:Canada gptkb:Japan gptkb:United_States |
| gptkbp:chemicalFormula |
IgG1 subclass
|
| gptkbp:clinicalTrials |
Phase 2
multiple centers worldwide Phase 3 ongoing monotherapy or in combination therapy increased progression-free survival L-MIND trial improved overall response rate |
| gptkbp:contraindication |
hypersensitivity to tafasitamab
|
| gptkbp:culturalEvents |
not_yet_approved_in_Europe
|
| gptkbp:developedBy |
gptkb:MorphoSys_AG
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
antibody-dependent cellular cytotoxicity
half-life of approximately 12 days |
| gptkbp:followedBy |
once every 2 weeks
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
relapsed or refractory DLBCL
|
| gptkbp:historical_analysis |
ongoing studies for other cancers
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tafasitamab
|
| gptkbp:impact |
until disease progression or unacceptable toxicity
|
| gptkbp:interactsWith |
live vaccines
|
| gptkbp:is_monitored_by |
complete blood counts
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:isTaskedWith |
other immunosuppressive agents
|
| gptkbp:lastProduced |
2020
|
| gptkbp:mandates |
B-cell malignancies
|
| gptkbp:marketedAs |
gptkb:Incyte_Corporation
brand_name_Monjuvi |
| gptkbp:origin |
humanized
|
| gptkbp:partnerships |
gptkb:Incyte_Corporation
|
| gptkbp:patentStatus |
patented
|
| gptkbp:patentType |
June 2020
|
| gptkbp:regulatoryCompliance |
approved
|
| gptkbp:researchFocus |
B-cell lymphomas
CD19 targeting therapies |
| gptkbp:route |
IV
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea infections cytopenia |
| gptkbp:targets |
CD19
|
| gptkbp:triggerType |
targets CD19
|
| gptkbp:usedFor |
treatment of relapsed or refractory diffuse large B-cell lymphoma
|
| gptkbp:variant |
lenalidomide
|